

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 12/17/1961  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Acid-Fast Bacillus (AFB) Culture and AFB Stain with Reflex to Mycobacterium tuberculosis Complex Detection and Rifampin Resistance by PCR**

ARUP test code 0060738

Collected: 00/00/0000 00:00 MT  
Started: 00/00/0000 00:00 MT

Source: **Respiratory**

Body Site: **Left Lower Lobe**

Free Text Sources: **BAL Bronchial Alveolar Lavage**

**Stains/Preparations**

**Acid Fast Stain**

Negative for Acid Fast Bacteria.

**Final Report**

Culture **POSITIVE** for  
Mycobacterium avium-intracellulare complex  
Identification by MALDI-TOF  
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Susceptibility Results**

**Organism: Mycobacterium avium-intracellulare complex**

<b>Amikacin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>2</b>
<b>Clarithromycin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>0.12</b>
<b>Linezolid</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>4</b>
<b>Moxifloxacin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>0.25</b>

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Non-susceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**Interpretive Information**

Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are <=64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Acid-Fast Bacillus (AFB) Culture and AFB Stain with Reflex to Mycobacterium tuberculosis Complex Detection and Rifampin Resistance by PCR	22-318-115370	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

*Unless otherwise indicated, testing performed at:*